US-based medical imaging and radiotherapy equipment provider United Imaging has received the US Food and Drug Administration (FDA) approval for its uMR Jupiter 5T MRI system.

uMR Jupiter is an advanced whole-body MRI system that addresses the conventional limitations of ultra-high-field imaging and represents a significant advancement in diagnostic radiology.

It is the first ultra-high field system approved for whole-body applications and is the first MRI device equipped with an eight-channel whole-body multi-transmit system.

United Imaging said that its uMR Jupiter 5T harnesses the power of ultra-high-field (UHF) magnet strength to offer enhanced resolution and a high signal-to-noise ratio.

It enables clinicians to visualise anatomical structures with superior clarity and detail.

United Imaging chairman and co-CEO Al Zhang said: “For decades, whole body applications above 3T have been elusive, and this system was targeted to open those doors. uMR Jupiter breaks new ground and defines a new technical category of systems. We are excited to be able to discuss this technology at ISMRM with the world.”

Building on its flexible design, the uMR Jupiter 5T extends imaging capabilities to previously challenging anatomical regions on UHF such as the heart, abdomen, and pelvis.

It represents an advanced technology that enables radiologists to detect and diagnose conditions with greater precision and confidence in a wider variety of exams.

United Imaging said the uMR Jupiter 5T is designed building on its proficiency in image uniformity and radiofrequency safety, two key challenges associated with ultra-high-field MRI.

Also, thoughtful design and meticulous engineering helped address the challenges, to ensure consistent image quality and patient safety, said the medical device maker.

United Imaging North America president and chief commercial officer Jeffrey Bundy said: “Our investments in R&D and in a highly efficient vertical integration strategy for our manufacturing have repeatedly led to breakthroughs – especially ones that help us achieve our mission of Equal Healthcare for All.

“We have always prioritized innovation that can make a broad clinical impact.

“Because it is aimed first and foremost at bringing ultra-high-field into greater clinical use, we believe it will have an exciting impact across our industry, and for clinical patients across the globe who have never had access to ultra-high-field in the past.”